Monopar Therapeutics Inc.
MNPR
$60.63
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.11% | 92.53% | 154.54% | 128.69% | 108.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.19% | -44.42% | 159.90% | 80.81% | 86.94% |
| Operating Income | -62.19% | 44.42% | -159.90% | -80.81% | -86.94% |
| Income Before Tax | -48.31% | 52.40% | -163.56% | -43.04% | -59.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.31% | 52.40% | -163.56% | -43.04% | -59.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.31% | 52.40% | -163.56% | -43.04% | -59.94% |
| EBIT | -62.19% | 44.42% | -159.90% | -80.81% | -86.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -21.40% | 72.65% | -30.23% | 28.41% | 26.84% |
| Normalized Basic EPS | -21.42% | 72.65% | -30.22% | 28.40% | 26.85% |
| EPS Diluted | -21.40% | 72.65% | -30.23% | 28.41% | 26.84% |
| Normalized Diluted EPS | -21.42% | 72.65% | -30.22% | 28.40% | 26.85% |
| Average Basic Shares Outstanding | 22.15% | 74.06% | 102.36% | 99.78% | 118.63% |
| Average Diluted Shares Outstanding | 22.15% | 74.06% | 102.36% | 99.78% | 118.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |